Apixaban zur Behandlung des emabilischen Schlafanfalls unbekannten Ursprungs Apixaban zur Behandlung des emabilischen Schlafanfalls unbekannten Ursprungs

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005109-19

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary endpoint will be the occurrence of at least one new ischemic lesion identified by magnetic resonance imaging (axial T2-weighted fluid attenuated inversion recovery MRI (FLAIR) and/ or axial diffusion weighted MRI (DWI)) at 12 months when compared to the baseline MRI (FLAIR, DWI) obtained at the time of study drug initiation. MRI at 12 months will be directly compared with the baseline MRI to assess for new ischemic lesions


Critère d'inclusion

  • Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism

Liens